Differences between dextroamphetamine and methamphetamine: Behavioral changes and oxidative damage in brain of Wistar rats

Journal of Neural Transmission

Volumn 119, Issue 1, 2012, Pages 31-38

  Da Rosa, Dayane D ^a   Valvassori, Samira S ^a   Steckert, Amanda V ^a   Arent, Camila O ^a   Ferreira, Camila L ^a   Lopes Borges, Jéssica ^a   Varela, Roger B ^a   Mariot, Edemilson ^a   Dal Pizzol, Felipe ^a   Andersen, Monica L ^b   Quevedo, João ^a,c  

^a Health Sciences Unit   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Dextroamphetamine; Exploratory Activity; Locomotor activity; Methamphetamine; Oxidative damage

Indexed keywords

DEXAMPHETAMINE; METHAMPHETAMINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENCY; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RAT;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TIME FACTORS;

EID: 84857623999     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0691-9     Document Type: Article

References (60)

1. Andreazza AC, Kauer-Sant'Anna M, Frey BN, Stertz L, Zanotto C, Ribeiro L et al (2008) Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci 33:516-524
2. Balster RL, Schuster CR (1973) A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys. Pharmacol Biochem Behav 1:67-71. doi: 10.1016/0091-3057(73)90057-9
3. Barros DM, Izquierdo LA, Medina JH, Izquierdo I (2002) Bupropion and sertraline enhance retrieval of recent and remote long-term memory in rats. Behav Pharmacol 13:215-220 (Pubitemid 34816466)
4. Björklund A, Dunnett SB (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci 30:194-202 (Pubitemid 46654237)
5. Burrows KB, Gudelsky G, Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3, 4- methylenedioxymethamphetamine administration. Eur J Pharmacol 398:11-18. doi:10.1016/S0014-2999(00)00 264-8 (Pubitemid 30336672)
6. Cadet JL, Jayanthi S, Deng X (2005) Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Neurotoxicity Research 8:199-206. doi:10.1007/ BF03033973
7. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE et al (2003) Heat increases 3, 4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 482:339-341 (Pubitemid 37505963)
8. Dawson VL, Dawson TM (1996) Nitric oxide neurotoxicity. J Chem Neuroanat 10:179-190 (Pubitemid 26197684)
9. Deng X, Cai NS, McCoy MT, Chen W, Trush MA, Cadet JL (2002) Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology 42:837-845. doi:10.1016/S0028-3908(02)00034-5 (Pubitemid 34518283)
10. Dietrich J, Mangeol A, Revel M, Burgun C, Aunis D, Zwiller J (2005) Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidantenzymeactivity in dopaminergic rat brain structures. Neuropharmacology 48:965-974. doi:10.1016/j.neuropharm.2005.01.018 (Pubitemid 40602604)
11. Draper HH, Hadley M (1990) Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 186:421-431. doi: 10.1016/0076-6879(90) 86135-I (Pubitemid 20279983)
12. Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54:1344-1349 (Pubitemid 30174057)
13. Fischer JF, Cho AK (1979) Chemical release of dopamine from striatal homogenates: Evidence for an exchange diffusion model. J Pharmacol Exp Ther 208:203-209 (Pubitemid 9191709)
14. Frey BN, Martins MR, Petronilho FC, Dal-Pizzol F, Quevedo J, Kapczinski F (2006a) Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 8:275-280. doi:10.1111/j.1399-5618. 2006.00318.x
15. Frey BN, Martins MR, Petronilho FC, Dal-Pizzol F, Quevedo J, Kapczinski F (2006b) Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 8:275-280. doi:10.1111/j.1399-5618.2006. 00318.x
16. Frey BN, Valvassori SS, Gomes KM, Martins MR, Dal-Pizzol F, Kapczinski F et al (2006c) Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 1097:224-229. doi:10.1016/j.brainres. 2006.04.076 (Pubitemid 44041287)
17. Frey BN, Valvassori SS, Réus GZ, Martins MR, Petronilho FC, Bardini K et al (2006d) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31:326-332 (Pubitemid 44497429)
18. Garthwaite J (1991) Glutamate, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci 14:60-67. doi:10.1016/ 0166-2236(91)90022-M
19. Gonzales R, Mooney L, Rawson RA (2010) The methamphetamine problem in the United States. Annu Rev Public Health 31:385-398. doi:10.1146/annurev. publhealth.012809.103600
20. Hall DA, Stanis JJ, Marquez Avila H, Gulley JM (2008) A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology (Berl). 195:469-478. doi: 10.1007/s00213-007-0923-8 (Pubitemid 350160487)
21. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716 (Pubitemid 32948277)
22. Hoffman BB, Lefkowitz RJ (1996). Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In:Hardman JG, Limbird LE, Molinoff PB, et al. (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill, New York, pp 199-227
23. Halliday G, Harding A, Paxinos G (1995) Serotonin and tachykinin systems. In: Paxinos G (ed) The rat nervous system, 2nd edn. Academic, San Diego, pp 929-974
24. Kopin IJ (1993) The pharmacology of Parkinson's disease therapy: an update. Annu Rev Pharmacol Toxicol 33:467-495 (Pubitemid 23116015)
25. Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308-1317
26. Kuhn DM, Appel JB, Greenberg I (1974) An analysis of some discriminative properties of d-amphetamine. Pharmacologia 39:57-66
27. Lai YL, Rodarte JR, Hyatt RE (1977) Effect of body position on lung emptying in recumbent anesthetized dogs. J Appl Physiol 43:983-987 (Pubitemid 8258269)
28. Lamb RJ, Henningfield JE (1994) Human d-amphetamine drug discrimination: methamphetamine and hydromorphone. J Exp Anal Behav 61:169-180. doi:10.1901/jeab.1994.61-169
29. Levine RL, Williams JA, Stadtman ER, Shacter E (1994) Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 233:346-357
30. London ED, Simon SL, BermanSMet al (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61:73-84 (Pubitemid 38044643)
31. Lorez H (1981) Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of methamphetamine. Life Sci 28:911-916 (Pubitemid 11099949)
32. Mathias R (1998). NIDA initiative tackles methamphetamine use. NIDA Notes 13
33. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C] WIN-35, 428. J Neurosci 18:8417-8422 (Pubitemid 28465016)
34. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK (1995) Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274:90-96
35. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME (1997) Recovery of striatal dopamine function after acute amphetamine and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766:113-120 (Pubitemid 27431441)
36. Milesi-Hallé A, McMillan DE, Laurenzana EM, Byrnes-Blake KA, Owens SM (2007) Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacol Biochem Behav 86:140-149. doi:10.1016/j.pbb.2006.12.018 (Pubitemid 46274979)
37. Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8:1445-1449. doi:10.1038/nn1578 (Pubitemid 41573654)
38. Nordahl TE, Salo R, Leamon M (2003) Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 15:317-325 (Pubitemid 36999374)
39. Olanow CW (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32:2-9
40. Poon HF, Calabrese V, Scapagnini G, Butterfield DA (2004) Free radicals and brain aging. Clin Geriatr Med 20:329-359. doi: 10.1016/j.cger.2004.02.005 (Review) (Pubitemid 38746444)
41. Ricaurte GA, Fuller RW, Perry KW, Seiden LS, Schuster CR (1983) Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of d-methamphetamine and d-amphetamine. Neuropharmacology 22:1165-1169. doi:10.1016/0028-3908(83) 90075-8 (Pubitemid 14213034)
42. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of (±)-3, 4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemicral observations. J Pharmacol Exp Ther 261:616-622
43. Robinson JB (1985) Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochem Pharmacol 34:4105-4108. doi:10.1016/0006-2952(85)90201-1 (Pubitemid 16195470)
44. Schaeffer JC, Cho AK, Fischer JF (1976) Inhibition ofthe sinaptosomal accumulation of l-norepinephrine. H. N-aryloxyalkylphentermines, quaternary d-amphetamines and 3-aryloxypropylamines. J Pharm Sd 65:122-126
45. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2005) Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterisation. Psychopharmacology 180:501-512 (Pubitemid 40905039)
46. Seiden LS, Fischman MW, Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215-219
47. Sekine Y, Iyo M, Ouchi Y et al (2001) Methamphetaminerelated psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214 (Pubitemid 32717692)
48. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175:63-69 (Pubitemid 29307857)
49. Shoblock JR, Sullivan EB, Maisonneuve IM, Glick SD (2003) Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl) 165:359-369. doi:10.1007/s00213-002-1288-7 (Pubitemid 36223077)
50. Sims DE (1991) Recent advances in pericyte biology-implications for health and disease. Can J Cardiol 7:431-443
51. Sonnewald U, Hertz L, Schousboe A (1998) Mitochondrial heterogeneity in the brain at the cellular level. J Cereb Blood Flow Metab 18:231-237 (Pubitemid 28103630)
52. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE (2005) Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J Neurosci Res 79:231-239 (Pubitemid 40116440)
53. Tata DA, Yamamoto BK (2007) Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction Suppl 1:49-60. doi:10.1111/j.1360-0443.2007.01770.x (Pubitemid 46328208)
54. UNODC-United Nations Office of Drugs on Crime (2007). World Drug Report. Vienna, Austria: UNODC
55. Valvassori SS, Petronilho FC, Réus GZ, Steckert AV, Oliveira VB, Boeck CR et al (2008) Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 32:1064-1068. doi:10.1016/j.pnpbp.2008.02. 012 (Pubitemid 351609248)
56. Valvassori SS, Moretti M, Kauer-Sant'Anna M, Roesler R, Petronilho F, Schwartsmann G et al (2010a) Effects of a gastrin-releasing peptide receptor antagonist on D-amphetamine-induced oxidative stress in the rat brain. J Neural Transm 117:309-316. doi: 10.1007/s00702-010-0373-z
57. Valvassori SS, Rezin GT, Ferreira CL, Moretti M, Gonçalves CL, Cardoso MR et al (2010b) Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 44:903-909. doi: 10.1016/j.jpsychires.2010.02.009
58. White FJ, Kalivas PW (1998) Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51:141-153. doi:10.1016/S0376-8716(98) 00072-6 (Pubitemid 28353762)
59. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS (1989) Longterm effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486:73-78 (Pubitemid 19102851)
60. Yokel RA, Pickens R (1973) Self-administration of optical isomers of amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther 187:27-33